Trevi Therapeutics/$TRVI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Trevi Therapeutics
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
- Ticker
- $TRVI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 34
- Headquarters
- New Haven, United States
- Website
- www.trevitherapeutics.com
TRVI Metrics
BasicAdvanced
$1.8B
-
-$0.35
1.07
-
Price and volume
Market cap
$1.8B
Beta
1.07
52-week high
$20.22
52-week low
$9.28
Average daily volume
2.3M
Financial strength
Current ratio
37.283
Quick ratio
36.684
Long term debt to equity
0.001
Total debt to equity
0.002
Profitability
EBITDA (TTM)
-59.42
Effective tax rate (TTM)
0.14%
Management effectiveness
Return on assets (TTM)
-13.82%
Return on equity (TTM)
-19.66%
Valuation
Price to book
5.73
Price to tangible book (TTM)
5.73
Price to free cash flow (TTM)
-35.62
Free cash flow yield (TTM)
-2.81%
Free cash flow per share (TTM)
-0.363
Growth
Earnings per share change (TTM)
-14.88%
3-year earnings per share growth (CAGR)
5.10%
What the Analysts think about TRVI
Analyst ratings (Buy, Hold, Sell) for Trevi Therapeutics stock.
Analyst projections of the future price of Trevi Therapeutics stock.
Bulls say / Bears say
Earlier CORAL results showed Haduvio at the selected 54 mg dose cut cough frequency by 36.5% versus placebo, with improvements in cough severity and daily impact. There are no approved treatments specifically for IPF-related chronic cough, leaving room for a useful therapy if the result holds up. (Pulmonary Fibrosis News)
Trevi says it has FDA alignment on the pivotal IPF programme and has started its first Phase 3 trial. A second Phase 3 study is planned, giving the company a defined route to test Haduvio in its lead indication. (SEC)
Trevi reported $318.9 million in cash, cash equivalents and marketable securities at the end of June 2026, and expects its runway to extend into 2030. It says this should fund the IPF programme through potential approval and support Phase 3 development in non-IPF ILD, reducing near-term financing pressure. (SEC)
Haduvio is still investigational, and Trevi expects OCEAN-1 Phase 3 results only in the first half of 2028. Investors face a long wait and substantial clinical risk before the lead programme can support a potential approval. (SEC)
Management said enrolment in its active trials was still at an early stage in August, despite plans to open more than 200 global sites. Recruitment delays could push back the company’s clinical milestones. (earningscalls.dev)
The stated cash plan excludes commercial launch costs and a Phase 3 trial in refractory chronic cough. Funding those steps may require additional capital, which could dilute shareholders. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.
TRVI Financial Performance
Revenues and expenses
TRVI Earnings Performance
Company profitability
Upcoming events
No upcoming events
TRVI News
AllArticlesVideos
Funds containing TRVI
AllUSDGBPEUR
Fund name | Fund size | $TRVI weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.13% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.13% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.05% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.05% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.